The "secret update"?

EUnetHTA Deliverable 4.2 on the PICO scoping process

Tue, 2023 / 12 / 19
EUnetHTA 21's authority to issue guidance documents on the upcoming EU HTA process ended with the expiry of the service contract on September 16th, 2023. A revised version of Deliverable 4.2, "Scoping Process" (version 1.1), is however now available. The publication date was stated as August 25th, 2023, but the update was never officially communicated.

Changes of version 1.1

The changes in the new deliverable include a glossary and a detailed description of the start of the PICO scoping in the individual member states by a basic PICO scheme, which will be developed by the responsible assessors. According to the update, the assessors shall work out a consolidated PICO proposal once they have received relevant information on the therapeutic indication from the following sources:

  • European guidelines for the disease area to obtain information on the natural history of the disease, available therapy alternatives, and relevant endpoints,
  • Alternative guideline documents (if no European guidelines have been identified for the disease area of the claimed therapeutic indication),
  • Clinical opinions from relevant experts in the field of application.

Furthermore, Member States should provide additional PICO(s) and subpopulations when responding to the PICO scoping if the assessors' proposal does not fully cover their national requirements. The guidance further states that in cases where there is no suitable comparator for all patients in a given population (in heterogeneous subpopulations and in the absence of a clearly defined evidence-based standard of care), the different treatment options and comparators should be regrouped as so-called "individualized treatment", similar to the "patient-individualized therapy" known in Germany, and a PICO should also be distinctly defined for "individualized treatment". The document further includes new details about the process of reducing the total number of PICO schemes during the PICO consolidation.

With the probable postponement of the publication of the first Implementing Act on JCA to Q1 2024, the new guidance document brings new insights into the implementation of the PICO scoping process, which will be of high strategic importance for the market access process of future drugs. Which of the proposed amendments will ultimately be adopted in the legally binding Implementing Act will, however, only become clear after its publication.

If you are looking for a strategic partner to achieve the greatest possible planning certainty for your product's EU HTA process in view of the current situation or need further insights into the current changes to the scoping process, please do not hesitate to contact us. We are the market access special forces.

Sources:

  • EUnetHTA 21 Deliverable 4.2, Version 1.0 (currently not available)
  • EunetHTA 21 Deliverable D4.2, Version 1.1 (currently not available)
  • We will be happy to provide you with the sources on request.

About the author

Ihr Ansprechpartner  Joey Rehkopf
Joey Rehkopf
M. Sc. Molecular Microbiology
Fon: +49 511 64 68 14 – 0
Fax: +49 511 64 68 14 18

EU HTA: European Health Technology Assessment (JCA)


Achieve planning security: With us you can align your projects and your resource planning comprehensively and at an early stage on EU HTA and its implications for market access.

Whitepaper


One HTA to assess them all 2.0 - The strategic perspective on EU HTA updated
to the top